Of the 15 patients in whom side effects were observed, 7 (46

Of the 15 patients in whom side effects were observed, 7 (46.7%) of the patients were provided IVIG treatments for FDA approved diseases and 8 (53.33%) were provided IVIG treatments without FDA approval. side effects included fever (n=5), headache (n=3), rash and redness (n=2), and pain in the infusion area, hypotension, and hypertension (n=1). Conclusion: Intravenous immunoglobulin preparations are used for the treatment of many diseases due to their immunoregulatory effects. In recent years, the use of IVIGs without FDA approval has been increasing. strong class=”kwd-title” Keywords: adverse effects, child, intravenous immunoglobulin, immunoregulatory Intravenous immunoglobulin (IVIG) preparations are plasma products obtained from healthy donors. Intravenous immunoglobulin therapy is usually primarily used as a replacement therapy for immunodeficient patients, but it can also be used for the treatment of many diseases, at high doses, due to its anti-inflammatory and immunoregulatory effects.1,2 The indications for US Food and Drug Administration (FDA) approved IVIG use include several diseases, such as main humoral immunodeficiency, immune thrombocytopenic purpura (ITP), Kawasaki disease (KD), chronic lymphocytic leukemia, and multifocal motor neuropathy. It has also been proven that IVIG therapy is beneficial for the treatment of many other diseases, such as Guillain-Barre syndrome (GBS), neonatal sepsis, neonatal blood type incompatibility, autoimmune hemolytic anemia (AHIA), and Stevens-Johnson syndrome.3-5 Although IVIGs are used at dosages of 400-500 mg/kg in replacement therapy, higher doses are used for immunoregulatory treatments.1,6 Several early onset side effects of IVIG use have been observed, including fever, rash, headache, nausea, vomiting, and myalgia, as well as late onset and severe side effects, including aseptic meningitis, acute kidney failure, thromboembolic events, hemolytic anemia, and myocardial infarctions. Even though incidence of IVIG-related side effects differs among previous studies, it has been reported to range from 3-20%.7-10 The aim of this study was to determine the demographic features of inpatients receiving IVIG therapy for immunoregulatory treatment, and to evaluate the indications for and side effects of IVIG therapy in a tertiary pediatrics hospital. Methods Patients who received IVIG therapy between January 2016 and August 2018 at the University Cd163 or college of Health Sciences, Ankara Tegoprazan Child Health and Diseases Hematology Oncology Training and Research Hospital (which is a tertiary pediatrics hospital), Ankara, Turkey, were retrospectively recognized from the patient file registry system. Patients who underwent IVIG treatments as replacement therapy were excluded from the study. Additionally, 17 patients were excluded due to insufficient information. Therefore, a total of Tegoprazan 186 patients with total data available from your file registry system were included in this study. The following information was recorded for each individual: demographic features, diagnosis, inpatient service in which they were followed-up, IVIG dosage, quantity of IVIG treatment days, and whether or not IVIG-related side effects occurred. It was determined that all of the patients who underwent IVIG therapy were provided antipyretics and antihistamines in order to reduce the side effects. In order to determine the IVIG-related side effects, we searched for the number of hospitalization days after the IVIG therapy. Those patients with follow-ups of longer than 2 weeks after the last IVIG dose were gathered into a single group. The side effects that occurred within the first 6 hours after the IVIG infusion were considered to be early onset side effects, and those that occurred between 6 hours and one week afterward were considered to be delayed onset side effects. The patients diagnoses were divided into 7 groups: neurological, hematological, dermatological, cardiological, rheumatic, infectious, and neonatal diseases. The use of IVIGs for the treatment of main humoral immunodeficiencies, ITP, KD, chronic lymphocytic leukemia, and multifocal motor neuropathy was found to be approved by the FDA. The protocol for this study was approved by the University or college of Health Sciences, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital Ethics Committee (number 2018/168). Statistical analysis The statistical data was calculated using the Statistical Package for Social Sciences (SPSS) version 18.0 for Windows (SPSS Inc, Chicago, IL, USA). A descriptive statistical analysis was conducted, and because the age at diagnosis was not normally distributed, the data Tegoprazan was expressed as the median and interquartile range. The qualitative data was expressed as number and percentage. The Chi-squared test was used to.